Sandbox Reserved 712: Difference between revisions
| Line 16: | Line 16: | ||
HIV protease inhibitors are the most potent agents used in anti-HIV treatment. However it appears that HIV-PRs develop a resistance to the inhibitor. <ref> PMID:12543689 </ref> | HIV protease inhibitors are the most potent agents used in anti-HIV treatment. However it appears that HIV-PRs develop a resistance to the inhibitor. <ref> PMID:12543689 </ref> | ||
3ggu (also PR<sub>DRV5</sub>) is a mutated clinically derived PR that shows phenotypical resistance to darunavir. Darunavir is a human immunodeficiency virus (HIV) protease (PR) inhibitor (PI) which has inhibiting effects on many HIV type 1 PR variants that show resistance to earlier-generation-PIs. <ref name="Molecular"> PMID:19535439 </ref> | 3ggu (also PR<sub>DRV5</sub>) is a mutated clinically derived PR that shows phenotypical resistance to darunavir. [[Darunavir]] is a human immunodeficiency virus (HIV) protease (PR) inhibitor (PI) which has inhibiting effects on many HIV type 1 PR variants that show resistance to earlier-generation-PIs. <ref name="Molecular"> PMID:19535439 </ref> | ||
== '''Darunavir: HIV-Protease Inhibitor''' == | == '''Darunavir: HIV-Protease Inhibitor''' == | ||